케토티펜과 올로파타딘로 농도에 따른 인간 제대혈 유래 비만세포의 안정화 평가

Blood-Derived Mast Cells in Accordance with Ketotifen and Olopatadine Concentration

Purpose: To evaluate the effect of olopatadine and ketotifen to stabilize mast cells using human umbilical cord blood-derived mast cells (hCBMCs). Methods: Using cultured hCBMCs, we divided the cells into the Ketotifen fumarate treatment group, the Olopatadine hydrochloride treatment group, the positive control group, and the negative control group. The histamine release inhibition rate was then observed. Results: Ketotifen and olopatadine both showed the highest inhibition rate of histamine release at a concentration of 10<sup>-3.5M (Ketotifen, 48% and Olopatadine, 62%). The histamine release inhibition rate of olopatadine was 28% at a concentration of 10<sup>-5.5M, but ketotifen demonstrated a low histamine release inhibition rate at the same concentration. Ketotifen and olopatadine showed no histamine release inhibition at concentrations of 10<sup>-2~10<sup>-2.5M, and 10<sup>-6M. Conclusions: Ketotifen and olopatadine demonstrated histamine inhibition in the concentration range of 10<sup>-3 to 10<sup>-5M. Olopatadine showed a slightly stronger response than ketotifen in the inhibition of histamine release.<br /> J Korean Ophthalmol Soc 2014;55(2):278-282